These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 18800146)

  • 1. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy.
    Misaghian N; Ligresti G; Steelman LS; Bertrand FE; Bäsecke J; Libra M; Nicoletti F; Stivala F; Milella M; Tafuri A; Cervello M; Martelli AM; McCubrey JA
    Leukemia; 2009 Jan; 23(1):25-42. PubMed ID: 18800146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Considerations for targeting malignant stem cells in leukemia.
    Guzman ML; Jordan CT
    Cancer Control; 2004; 11(2):97-104. PubMed ID: 15024346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Right on target: eradicating leukemic stem cells.
    Krause DS; Van Etten RA
    Trends Mol Med; 2007 Nov; 13(11):470-81. PubMed ID: 17981087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular targeted therapy for leukemic stem cells].
    Kikushige Y
    Nihon Rinsho; 2015 May; 73(5):811-5. PubMed ID: 25985636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted elimination of leukemia stem cells; a new therapeutic approach in hemato-oncology.
    ten Cate B; de Bruyn M; Wei Y; Bremer E; Helfrich W
    Curr Drug Targets; 2010 Jan; 11(1):95-110. PubMed ID: 20017722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukemia stem cells.
    Testa U
    Ann Hematol; 2011 Mar; 90(3):245-71. PubMed ID: 21107841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How close are we to targeting the leukemia stem cell?
    Pei S; Jordan CT
    Best Pract Res Clin Haematol; 2012 Dec; 25(4):415-8. PubMed ID: 23200537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells.
    Fan D; Li Z; Zhang X; Yang Y; Yuan X; Zhang X; Yang M; Zhang Y; Xiong D
    J Hematol Oncol; 2015 Feb; 8():18. PubMed ID: 25879549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the acute myeloid leukemia stem cells.
    Krause A; Luciana M; Krause F; Rego EM
    Anticancer Agents Med Chem; 2010 Feb; 10(2):104-10. PubMed ID: 20184541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New approaches to target leukemia stem cells].
    Takenaka K; Akashi K
    Nihon Rinsho; 2014 Jun; 72(6):1018-25. PubMed ID: 25016798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells.
    Pelosi E; Castelli G; Testa U
    Blood Cells Mol Dis; 2015 Dec; 55(4):336-46. PubMed ID: 26460257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.
    Jin L; Lee EM; Ramshaw HS; Busfield SJ; Peoppl AG; Wilkinson L; Guthridge MA; Thomas D; Barry EF; Boyd A; Gearing DP; Vairo G; Lopez AF; Dick JE; Lock RB
    Cell Stem Cell; 2009 Jul; 5(1):31-42. PubMed ID: 19570512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
    Hu Y; Chen Y; Douglas L; Li S
    Leukemia; 2009 Jan; 23(1):109-16. PubMed ID: 18818703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent progress on targeting leukemia stem cells.
    Ma XY; Wei L; Lei Z; Chen Y; Ding Z; Chen ZS
    Drug Discov Today; 2021 Aug; 26(8):1904-1913. PubMed ID: 34029689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that high-migration drug-surviving MOLT4 leukemia cells exhibit cancer stem cell-like properties.
    Huang X; Xiong M; Jin Y; Deng C; Xu H; An C; Hao L; Yang X; Deng X; Tu Z; Li X; Xiao R; Zhang Q
    Int J Oncol; 2016 Jul; 49(1):343-51. PubMed ID: 27210806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia.
    Kikushige Y; Miyamoto T
    Oncology; 2015; 89 Suppl 1():28-32. PubMed ID: 26551150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can we finally target the leukemic stem cells?
    Jordan CT
    Best Pract Res Clin Haematol; 2008 Dec; 21(4):615-20. PubMed ID: 19041600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.
    Kikushige Y; Shima T; Takayanagi S; Urata S; Miyamoto T; Iwasaki H; Takenaka K; Teshima T; Tanaka T; Inagaki Y; Akashi K
    Cell Stem Cell; 2010 Dec; 7(6):708-17. PubMed ID: 21112565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Progress in the studies of acute myelogenous leukemia stem cell].
    Cui JW; Zhang XM; Wang GJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Oct; 11(5):549-52. PubMed ID: 14575558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.
    McCubrey JA; Steelman LS; Abrams SL; Bertrand FE; Ludwig DE; Bäsecke J; Libra M; Stivala F; Milella M; Tafuri A; Lunghi P; Bonati A; Martelli AM
    Leukemia; 2008 Apr; 22(4):708-22. PubMed ID: 18337766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.